Distinguished Scientific and Clinical Leader to Join Enochian BioSciences’ Hepatitis B Cure Scientific Advisory Board
August 23 2021 - 10:18AM
(NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene
modified cellular and immune therapies for infectious diseases and
cancer, announced that the renowned Dr. Anna Suk-Fong Lok, MD, has
joined the Scientific Advisory Board for a potential cure for
Hepatitis B Virus (HBV), that causes liver disease in approximately
350 million people globally and 1 million deaths every year.
Professor Lok is a leading clinical researcher. She is the Alice
Lohrman Andrews Research Professor in Hepatology in the Department
of Internal Medicine, at Michigan Medicine in Ann Arbor, Michigan
and is the Director of Clinical Hepatology and Assistant Dean for
Clinical Research in the University of Michigan Medical School.
Dr. Lok's research focuses on the natural history and treatment
of hepatitis B and C, and the prevention of liver cancer. She has
published more than 550 papers on viral hepatitis and liver
diseases, and has co-authored five editions of the American
Association for the Study of Liver Diseases (AASLD) Guidelines on
Hepatitis B. She is a former President of the AASLD. Dr. Lok
was one of the top 1% of most cited scientists in the world for the
decade 2002-2012.
“I was intrigued by Enochian’s Inventor and Co-Founder, Dr.
Serhat Gumrukçu’s presentation at an important scientific meeting
in December 2019, where he cited the early data and very innovative
strategy to potentially cure HBV. Since then, the Company has made
significant progress and I am very pleased to now become more
engaged and contribute to advancing the science towards clinical
trials,” Dr. Lok said. Dr. Carol Brosgart, the Chair of the
Scientific Advisory Board and member of the Enochian Board of
Directors, said, “I am very excited that Anna is joining Dr. Fabien
Zoulim and Dr. Peter Revill as members of the Scientific Advisory
Board. Anna brings decades-long expertise in clinical research.
They are all among the top researchers in the field of Hepatitis,
creating a remarkably high-powered group.”
“Enochian is entering a key phase to accelerate the development
of a potential cure for HBV with promising results thus far,” said
Dr. Mark Dybul, Enochian’s CEO. “As announced previously, the FDA
accepted our Pre-Investigational New Drug (IND) application. As we
prepare to advance through the regulatory process, it is timely for
someone with Anna’s extensive clinical research expertise to join
our Scientific Advisory Board.”
About Enochian BioSciences, Inc. Enochian
BioSciences, Inc. is a biopharmaceutical company focused on
developing innovative platforms for gene-modified cellular and
immune therapies to potentially cure and treat deadly diseases. The
company’s gene-modified cell and immune therapy platforms can
potentially be applied to multiple indications, including HIV/AIDS,
Hepatitis B, all Corona and Influenza viruses, and Oncology. For
more information, please visit Enochianbio.com
Forward-Looking Statements Statements in this
press release that are not strictly historical in nature are
forward-looking statements. These statements are only predictions
based on current information and expectations and involve a number
of risks and uncertainties, including but not limited to the
success or efficacy of our pipeline. All statements other than
historical facts are forward-looking statements, which can be
identified by the use of forward-looking terminology such as
“believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or
similar expressions. Actual events or results may differ materially
from those projected in any of such statements due to various
uncertainties, including as set forth in Enochian BioSciences’ most
recent Annual Report on Form 10-K filed with the SEC. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement, and Enochian BioSciences undertakes no
obligation to revise or update this press release to reflect events
or circumstances after the date hereof.
Contact: ir@enochianbio.com
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Apr 2023 to Apr 2024